I’d buy this FTSE 100 stock without hesitation

Finding the right investments can be a challenge, but I’ve found one FTSE 100 stock that ticks all the boxes for my long-term portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In today’s volatile market, finding reliable stocks that offer both stability and growth can be challenging. However, there are plenty of FTSE 100 stocks that stand out to me as compelling investments. Here’s one I’d buy at the next opportunity.

AstraZeneca

AstraZeneca (LSE:AZN), the biopharmaceutical giant, is my first pick in the FTSE 100. With a market cap of £191.4bn, it’s a heavyweight in the pharmaceuticals industry, focusing on discovering, developing, and commercialising prescription medicines.

According to a discounted cash flow (DCF) calculation, the firm is currently trading at a staggering 34.9% below its estimated fair value. Of course, this isn’t a guarantee of value, but definitely shows potential.

The company’s future looks bright. Analysts forecast annual earnings growth of about 15% over the coming few years, indicating strong potential for capital appreciation. This growth isn’t just speculative. Earnings grew by an impressive 34.6% over the past year, demonstrating its ability to deliver robust financial results.

Ticking the final box for me, AstraZeneca offers a reliable dividend yield of 2%. Although not the highest in the market, the company’s payout ratio of 71% suggests the dividend is sustainable, especially considering its strong earnings growth.

Product line-up

The company’s success is underpinned by its robust product line-up. Key drugs like Tagrisso, Imfinzi, and Lynparza in oncology, Farxiga in diabetes, and Breztri in respiratory diseases are driving revenue growth. By building a strategic focus on high-growth areas like oncology and rare diseases positions, the business appears well positioned for the future.

During the pandemic, AstraZeneca gained global recognition for its Vaxzevria Covid vaccine. But its story doesn’t end there. Recent updates show continued innovation, such as positive results from the Phase III trial of Sipavibart, a long-acting antibody for preventing Covid in immunocompromised patients. This demonstrates AstraZeneca’s adaptability and commitment to addressing urgent medical needs, which may set it apart from other companies in the sector.

Risks

Of course it’s not all good news. There’s also a huge amount of competition to consider here. With many companies racing to approval for new products, problems in development can have enormous repercussions.

The financials also show some areas of concern, such as a high level of debt, but for me it’s essential to view this in the right context. High debt is never good, but it’s also common in the pharmaceutical industry, where companies invest heavily in R&D to develop new, potentially blockbuster drugs.

The price-to-earnings (P/E) ratio of the company at 39.2 times is also pretty high, and significantly above the average of the sector at 25.7 times. With plenty of future earnings seemingly in the share price already, any disappointment could lead to a major sell-off.

Overall

In summary, AstraZeneca offers a compelling mix of undervaluation, strong growth prospects, stable dividends, and a robust product portfolio. Despite some financial concerns, its strategic focus and proven ability to deliver make it a FTSE 100 stock I’d buy without hesitation. When I next have cash available, I’ll be picking up as many shares as I can.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Gordon Best has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Why isn’t everyone aiming for £37m in stocks and shares?

It’s never too early to start investing in stocks and shares through a SIPP or ISA. Dr James Fox explains…

Read more »

Happy couple showing relief at news
Investing Articles

Here’s how much an investor needs in an ISA to generate a £27,500 second income

Imagine creating a second income that's the equivalent of the average post-tax salary in the UK. Dr James Fox explains…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Here’s the Tesco share price forecast for the next 12 months!

Tesco's valuation has dropped to multi-year lows after recent share price weakness. Is now the time to consider buying the…

Read more »

Illustration of flames over a black background
Investing Articles

Just released: March’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

Investing Articles

I asked ChatGPT for the best FTSE 100 investment trust to buy… here’s what it said

There aren't many FTSE 100-listed investment trusts and according to ChatGPT there’s only one winner. Dr James Fox explores.

Read more »

Investing Articles

How much should investors put in an ISA to achieve the average UK wage in passive income?

Millions of Britons use the Stocks and Shares ISA as a vehicle to build wealth, but a successful investor can…

Read more »

Investing Articles

2 cheap FTSE dividend stocks to consider buying for an ISA

The deadline for using up the Stocks and Shares ISA allowance is almost upon us. Paul Summers has spotted two…

Read more »

Investing Articles

£20k in a Stocks and Shares ISA? Here’s how an investor could target £1,342 in passive income each month

Christopher Ruane explains how a long-term approach to investing a Stocks and Shares ISA could generate a four-figure monthly income.

Read more »